Cargando…

Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway

BACKGROUND: Targeting differentially activated or perturbed tumour pathways is the key idea in individualised cancer therapy, which is emerging as an important option in treating cancers with poor prognostic profiles. TP53 mutation status is known as a core determinant of survival in breast cancer....

Descripción completa

Detalles Bibliográficos
Autores principales:	Joshi, H, Bhanot, G, Børresen-Dale, A-L, Kristensen, V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493873/ https://www.ncbi.nlm.nih.gov/pubmed/23079576 http://dx.doi.org/10.1038/bjc.2012.461

Ejemplares similares

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy
por: Oden-Gangloff, A, et al.
Publicado: (2009)

Unique volatolomic signatures of TP53 and KRAS in lung cells
por: Davies, M P A, et al.
Publicado: (2014)

HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53
por: Meulendijks, D, et al.
Publicado: (2015)

TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival
por: Wang, Y, et al.
Publicado: (2004)

The proline TP53 variant stimulates likely lymphangiogenesis in an orthotopic mouse model of pancreatic cancer
por: Otto, N, et al.
Publicado: (2012)

PICT1 regulates TP53 via RPL11 and is involved in gastric cancer progression
por: Uchi, R, et al.
Publicado: (2013)

The BMP pathway either enhances or inhibits the Wnt pathway depending on the SMAD4 and p53 status in CRC
por: Voorneveld, P W, et al.
Publicado: (2015)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma
por: Pritchard-Jones, R O, et al.
Publicado: (2007)

Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer
por: Kut, C, et al.
Publicado: (2007)

VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo
por: Rennel, E S, et al.
Publicado: (2009)

Restoration of TGF-β signalling reduces tumorigenicity in human lung cancer cells
por: Anumanthan, G, et al.
Publicado: (2005)

The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer
por: Trinh, X B, et al.
Publicado: (2009)

Inactivation of the WASF3 gene in prostate cancer cells leads to suppression of tumorigenicity and metastases
por: Teng, Y, et al.
Publicado: (2010)

VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2
por: Gavalas, N G, et al.
Publicado: (2012)

SOX2 regulates self-renewal and tumorigenicity of stem-like cells of head and neck squamous cell carcinoma
por: Lee, S H, et al.
Publicado: (2014)

No relationship between thymidine phosphorylase (TP, PD-ECGF) expression and hypoxia in carcinoma of the cervix
por: Kabuubi, P, et al.
Publicado: (2006)

Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression
por: Couvelard, A, et al.
Publicado: (2005)

Nuclear CSPP1 expression defined subtypes of basal-like breast cancer
por: Sternemalm, J, et al.
Publicado: (2014)

Tumour morphology predicts PALB2 germline mutation status
por: Teo, Z L, et al.
Publicado: (2013)

Tumour mutation status and sites of metastasis in patients with cutaneous melanoma
por: Adler, Nikki R, et al.
Publicado: (2017)

Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma
por: Yoshikawa, D, et al.
Publicado: (2008)

Intracrine VEGF signalling mediates colorectal cancer cell migration and invasion
por: Bhattacharya, Rajat, et al.
Publicado: (2017)

TP53 gene mutations and protein accumulation in primary vaginal carcinomas.
por: Skomedal, H., et al.
Publicado: (1995)

Mutation status among patients with sinonasal mucosal melanoma and its impact on survival
por: Amit, Moran, et al.
Publicado: (2017)

SILAC-based phosphoproteomics reveals an inhibitory role of KSR1 in p53 transcriptional activity via modulation of DBC1
por: Zhang, H, et al.
Publicado: (2013)

TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer
por: Mukhopadhyay, Utpal K, et al.
Publicado: (2019)

Prognostic value of increase in transcript levels of Tp73 ΔEx2-3 isoforms in low-grade glioma patients
por: Wager, M, et al.
Publicado: (2006)

Gene expression profiles and the TP53 mutation status are powerful prognostic markers of breast cancer
por: Langerød, A, et al.
Publicado: (2005)

Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer
por: Hofstetter, G, et al.
Publicado: (2011)

Semaphorin, neuropilin and VEGF expression in glial tumours: SEMA3G, a prognostic marker?
por: Karayan-Tapon, L, et al.
Publicado: (2008)

Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer
por: Sasahira, T, et al.
Publicado: (2012)

Platelet releasate promotes breast cancer growth and angiogenesis via VEGF–integrin cooperative signalling
por: Jiang, Lei, et al.
Publicado: (2017)

Expression of wild-type and mutated TP53 in breast carcinomas
por: Baumbusch, LO, et al.
Publicado: (2005)

Excess of miRNA-378a-5p perturbs mitotic fidelity and correlates with breast cancer tumourigenesis in vivo
por: Winsel, S, et al.
Publicado: (2014)

Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy
por: Zlobec, I, et al.
Publicado: (2008)

HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium
por: Kurosu, T, et al.
Publicado: (2011)

Stabilisation of p53 enhances reovirus-induced apoptosis and virus spread through p53-dependent NF-κB activation
por: Pan, D, et al.
Publicado: (2011)

Mitochondrial DNA mutations in renal cell carcinomas revealed no general impact on energy metabolism
por: Meierhofer, D, et al.
Publicado: (2006)

TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer
por: Langerød, Anita, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_1u4i060h9epsodtghrmp5hc1hi